CD200 and B-cell chronic lymphocytic leukemia: Both studies were terminated, but the second one published results showing that administration of the drug was associated with reduced expression of CD200 on B-cells and CD4+ effector T-cells of B-CLL individuals, however inefficient in the three myeloma patients evaluated (166).